Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Anange Lwilla

Biographic Data

ID9068726
NAMEAnange Lwilla
GIVEN NAMESAnange
FAMILY NAMELwilla
SIGNATURELWILLA A
AFFILIATIONSNational Institute for Medical Research
ORCID0000-0002-8011-6948
VERIFIEDYes
TOTAL WORKS4
TOTAL CITATIONS0
WORKS AS AUTHOR4
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2023
LATEST PUBLICATION YEAR2025
H-INDEX0
  • An extended cost-effectiveness analysis of decentralised TB diagnostic testing with Molbio Truenat MTB/RIF versus hub-and-spoke GeneXpert MTB/RIF in Mozambique and Tanzania

    Open Access•Saima Bashir, Lelisa Fekadu Assebe et al.•ARTICLE•BMJ Global Health•2025

    BACKGROUND: In low- and middle-income countries (LMICs), tuberculosis (TB) regained its status as the leading cause of death from a single infectious agent in 2023, surpassing COVID-19. Rapid and accurate diagnosis is critical, with decentralised diagnostic strategies offering a promising solution. Although decentralised diagnostic strategies have been proven cost-effective, further evidence is needed on affordability and equity in high-burden se…

  • Decentralized TB diagnostic testing with Truenat MTB Plus and MTB-RIF Dx vs. hub-and-spoke GeneXpert MTB/RIF Ultra in Mozambique and Tanzania

    Open Access•Akash Malhotra, Délio Elísio et al.•ARTICLE•PLOS Global Public Health•2025

    In low-and middle-income countries, missed or delayed tuberculosis (TB) diagnoses contribute to avoidable morbidity, mortality, and transmission. Decentralized testing platforms, such as the Molbio Truenat, may offer solutions by providing accurate point-of-care testing, improving access, and lowering out-of-pocket costs. Despite these advantages, the overall cost and cost-effectiveness of identifying additional TB cases using the Truenat MTB ass…

  • Optimizing delivery strategies for 3HP TB preventive treatment in Tanzania

    Open Access•Doreen Pamba, Erica Sanga et al.•ARTICLE•PLOS Global Public Health•2024

    Tanzania rolled-out a 12-dose, weekly regimen of isoniazid plus rifapentine (3HP) TB preventive treatment in January 2024. The 3HP completion rate is generally ≥80%, varying by delivery strategy and programmatic setting. Before the roll-out, a mixed methods study was conducted to assess whether a family approach involving family member support, SMS reminders, and three health education sessions was acceptable and optimized 3HP uptake and completi…

  • Early warning indicators of HIV drug resistance in the southern highlands region of Tanzania

    Open Access•Samoel Khamadi, Samoel A Khamadi et al.•ARTICLE•PLOS Global Public Health•2023

    The World Health Organization early warning indicators (EWIs) permit surveillance of factors associated with the emergence of HIV drug resistance (HIVDR). We examined cross- and within-region performance on HIVDR EWIs for selected HIV care and treatment clinics (CTCs) in five regions of southern Tanzania. We retrospectively abstracted EWI data from 50 CTCs for the January to December 2013 period. EWIs included the following: on time ART pick-up, …

No prominent works on this page.

  • Early warning indicators of HIV drug resistance in the southern highlands region of Tanzania

    Open Access•Samoel Khamadi, Samoel A Khamadi et al.•ARTICLE•PLOS Global Public Health•2023

    The World Health Organization early warning indicators (EWIs) permit surveillance of factors associated with the emergence of HIV drug resistance (HIVDR). We examined cross- and within-region performance on HIVDR EWIs for selected HIV care and treatment clinics (CTCs) in five regions of southern Tanzania. We retrospectively abstracted EWI data from 50 CTCs for the January to December 2013 period. EWIs included the following: on time ART pick-up, …

  • Optimizing delivery strategies for 3HP TB preventive treatment in Tanzania

    Open Access•Doreen Pamba, Erica Sanga et al.•ARTICLE•PLOS Global Public Health•2024

    Tanzania rolled-out a 12-dose, weekly regimen of isoniazid plus rifapentine (3HP) TB preventive treatment in January 2024. The 3HP completion rate is generally ≥80%, varying by delivery strategy and programmatic setting. Before the roll-out, a mixed methods study was conducted to assess whether a family approach involving family member support, SMS reminders, and three health education sessions was acceptable and optimized 3HP uptake and completi…

  • An extended cost-effectiveness analysis of decentralised TB diagnostic testing with Molbio Truenat MTB/RIF versus hub-and-spoke GeneXpert MTB/RIF in Mozambique and Tanzania

    Open Access•Saima Bashir, Lelisa Fekadu Assebe et al.•ARTICLE•BMJ Global Health•2025

    BACKGROUND: In low- and middle-income countries (LMICs), tuberculosis (TB) regained its status as the leading cause of death from a single infectious agent in 2023, surpassing COVID-19. Rapid and accurate diagnosis is critical, with decentralised diagnostic strategies offering a promising solution. Although decentralised diagnostic strategies have been proven cost-effective, further evidence is needed on affordability and equity in high-burden se…

  • Decentralized TB diagnostic testing with Truenat MTB Plus and MTB-RIF Dx vs. hub-and-spoke GeneXpert MTB/RIF Ultra in Mozambique and Tanzania

    Open Access•Akash Malhotra, Délio Elísio et al.•ARTICLE•PLOS Global Public Health•2025

    In low-and middle-income countries, missed or delayed tuberculosis (TB) diagnoses contribute to avoidable morbidity, mortality, and transmission. Decentralized testing platforms, such as the Molbio Truenat, may offer solutions by providing accurate point-of-care testing, improving access, and lowering out-of-pocket costs. Despite these advantages, the overall cost and cost-effectiveness of identifying additional TB cases using the Truenat MTB ass…

Tanzania (4 works) · Medicine (3 works) · Tuberculosis Research and Epidemiology (3 works) · Diagnostic test (2 works) · Family medicine (2 works) · GeneXpert MTB/RIF (2 works) · Geography (2 works) · HIV/AIDS Research and Interventions (2 works) · Pneumocystis jirovecii pneumonia detection and treatment (2 works) · Tuberculosis (2 works)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae